Loan losses (actual) of Bank OZK – NASDAQ:OZK

Jefferies Financial Group Inc. is in dispute with Glencore Plc over $526.4 million in overdue payments linked to Radiant World, an iron ore trader. Jefferies claims Glencore owes the amount, while Glencore denies any obligation. Emails show escalating tensions as Jefferies seeks information on invoices, with Glencore alleging Radiant World was involved in fraud. Radiant World and Sapphire Minmetals have filed a $2 billion lawsuit against Glencore, which denies the claims.

Morgan Stanley downgraded Novo Nordisk (NVO) to Underweight, citing concerns over semaglutide's patent expiration and its impact on revenue. The stock, trading at 10.6x earnings, fell 2% post-call. Analysts debate whether the multiple reflects a bargain or undervalues future growth. Hedge funds increased holdings, while short interest remains low.

Halliburton (HAL) secured a multi-year contract from Eni (E) for the Cronos ultra-deepwater project in Cyprus, covering integrated drilling and well services. The deal aims to boost revenue per well and improve operational efficiency, though profitability depends on pricing and delivery costs. HAL's Q2 Europe/Africa revenue rose 19% sequentially, partly driven by regional activity.

Baird downgraded NIKE (NKE), Dick's (DKS), adidas, Rocky Brands, and VF Corp to Neutral, citing consumer spending concerns due to oil prices and interest rates. NIKE and DKS are interconnected, with NIKE products making up 31% of DKS's merchandise. DKS shares fell 30% in August after lowering full-year expectations. Hedge fund holdings in DKS increased, while NIKE saw a decline. Baird's report suggests potential structural demand weakness in the footwear segment.

Jazz Pharmaceuticals (JAZZ) raised its revenue estimate for Ziihera to $3B-$5B, citing potential expansion in multiple cancer types. The company expects Ziihera to become a first-line standard of care for HER2-positive gastroesophageal adenocarcinoma. Jazz also announced pipeline expansions in epilepsy and sleep-wake disorders, including new clinical trials and formulations.

LifeMD (LFMD) partnered with AT&T to offer free virtual-health memberships to 29 million eligible customers in 11 states, with a nationwide expansion planned for 2027. The $19 monthly fee is waived, but services like visits and prescriptions remain payable. LifeMD aims to convert access into recurring demand for paid care, potentially reducing acquisition costs and benefiting from repeat consultations. The phased rollout allows for measuring enrollment and utilization before expansion.